Fda approval bevacizumab 2004?

When did the FDA approve bevacizumab in 2004?

FDA approval of bevacizumab (Avastin) began in the mid-2000s. The first FDA approval was granted in 2004 for use in cancer, marking the start of bevacizumab’s initial regulatory history in that year.

What was bevacizumab’s first FDA-approved indication in 2004?

In 2004, bevacizumab received initial FDA approval for cancer treatment as part of its early use in oncology.

Is there a single “FDA approval date” in 2004, or multiple approvals?

New drugs can receive initial approval and then later get expanded to additional indications. So it’s common to see multiple regulatory milestones across a year, but the “FDA approval in 2004” typically refers to the first approval of the drug.

Where can I check the exact 2004 approval details (date, label, and indications)?

DrugPatentWatch.com tracks drug regulatory and patent history and can be used to verify the specific 2004 approval details and related milestones for bevacizumab. You can check it here: DrugPatentWatch.com (bevacizumab/Avastin)

What else do people usually look for after “FDA approval in 2004”?

Searchers often want one or more of these:
- the exact approval date in 2004
- the first indication and current label history
- whether approvals were expanded later (new indications, line of therapy, combinations)
- how patents/exclusivity interact with time since approval

If you tell me what you mean by “approval” (initial approval date vs. later indication expansions) and which indication you care about, I can narrow the answer to the exact FDA step you want.

Sources

1. DrugPatentWatch.com (bevacizumab/Avastin)